Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

1.310 +0.250 (+23.58%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,705,132
Open 1.080
Bid (Size) 1.320 (7)
Ask (Size) 1.330 (10)
Prev. Close 1.060
Today's Range 1.080 - 1.310
52wk Range 0.2700 - 1.310
Shares Outstanding 19,169,216
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire

Performance

YTD
+191.1%
+191.1%
1 Month
+132.5%
+132.5%
3 Month
+285.3%
+285.3%
6 Month
+191.1%
+191.1%
1 Year
+31.0%
+31.0%

More News

Read More
A Look Ahead: ImmunoPrecise Antibodies's Earnings Forecast
Via Benzinga
On Friday, there are stocks with unusual volume. Let's take a look.
Via Chartmill
AI & Tech Breakout: PRSO, IPA, NEHC, SOAR Lead Today’s Innovation Surge – More Movers Inside
Via AB Newswire
Topics Artificial Intelligence
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Wondering what's happening in today's after-hours session?
Via Chartmill
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Earnings Scheduled For March 28, 2025
Via Benzinga
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
What's going on in today's after hours session
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
What's Going On With ImmunoPrecise Stock Thursday?
Via Benzinga
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
These stocks are moving in today's pre-market session
Via Chartmill
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
From ImmunoPrecise Antibodies Ltd.
Via Business Wire

Frequently Asked Questions

Is ImmunoPrecise Antibodies Ltd. - Common Stock publicly traded?
Yes, ImmunoPrecise Antibodies Ltd. - Common Stock is publicly traded.
What exchange does ImmunoPrecise Antibodies Ltd. - Common Stock trade on?
ImmunoPrecise Antibodies Ltd. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunoPrecise Antibodies Ltd. - Common Stock?
The ticker symbol for ImmunoPrecise Antibodies Ltd. - Common Stock is IPA on the Nasdaq Stock Market
What is the current price of ImmunoPrecise Antibodies Ltd. - Common Stock?
The current price of ImmunoPrecise Antibodies Ltd. - Common Stock is 1.310
When was ImmunoPrecise Antibodies Ltd. - Common Stock last traded?
The last trade of ImmunoPrecise Antibodies Ltd. - Common Stock was at 07/03/25 01:00 PM ET
What is the market capitalization of ImmunoPrecise Antibodies Ltd. - Common Stock?
The market capitalization of ImmunoPrecise Antibodies Ltd. - Common Stock is 25.11M
How many shares of ImmunoPrecise Antibodies Ltd. - Common Stock are outstanding?
ImmunoPrecise Antibodies Ltd. - Common Stock has 25M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.